Evaluation of Portal Vein Stenting in Patients With Portal Vein Stenosis and Gastrointestinal Cancers
Evaluation of Portal Vein Stenting in Patients With Portal Vein Stenosis and Gastrointestinal Cancers
This study collects information about the safety and effect of portal vein stenting in
 gastrointestinal cancer patients with portal vein stenosis. This study may help researchers
 learn how long the portal vein stays open and free from blockage and the effects of portal
 vein stenting on patients' overall well-being.
PRIMARY OBJECTIVE:

 I. To evaluate the safety and efficacy of portal vein stenting in patients with portal vein
 (PV) stenosis and gastrointestinal malignancies, including quality of life measurements.

 SECONDARY OBJECTIVES:

 I. Stent patency and duration of clinical success related to the intervention. II. Compare
 the efficacy of portal vein stenting on liver volumes, nutritional status, and laboratory
 values relative to patients with portal vein stenosis/thrombosis who do not undergo portal
 vein stenting.

 OUTLINE: Patients are assigned to 1 of 2 cohorts.

 COHORT A: Patients complete a quality of life (QoL) questionnaire at 2-4 weeks and then 6-8
 weeks after portal vein stenting procedure. Patients' medical records are also reviewed.

 COHORT B: Patients' medical records are reviewed retrospectively.
Inclusion Criteria:

 -  COHORT A: All patients will undergo initial staging and treatment as per the
 institution standard of care. Patients will be considered eligible for
 porto-mesenteric venous stenting (PVS) if:

 -  There is > 75% porto-mesenteric venous stenosis in either main portal vein (PV),
 left PV, right PV, or the superior mesenteric vein (SMV), even in absence of
 symptoms of portal hypertension

 -  Patients presented with any degree of vascular narrowing of said vessels and
 symptomatic portal hypertension including variceal bleeding, refractory ascites,
 abdominal pain, intestinal edema, or diarrhea after exclusion of tumor-related
 causes as direct tumor invasion or peritoneal dissemination

 -  COHORT B: Patients who have thrombosis/stenosis of the main portal vein but who did
 not undergo stenting